PedAM
Pediatric Disease Annotations & Medicines
| Disease | bronchitis |
| Phenotype | C0024117|chronic obstructive pulmonary disease (copd) |
| Sentences | 8 |
| PubMedID- 22723325 | Context: the phosphodiesterase 4 inhibitor roflumilast is a first-in-class antiinflammatory treatment for severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and a history of frequent exacerbations. |
| PubMedID- 23392624 | Objective: to estimate the cost-effectiveness of adding a selective phosphodiesterase-4 inhibitor, roflumilast, to a long-acting bronchodilator therapy (laba) for the treatment of patients with severe-to-very severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis with a history of frequent exacerbations from the uk payer perspective. |
| PubMedID- 23865594 | In the post-hib vaccine era, non-typeable h. influenzae (nthi) continue to cause infections of the respiratory tree including otitis media (om), conjunctivitis, sinusitis, pneumonia, and bronchitis especially in patients with chronic obstructive pulmonary disease (copd); as well as playing a role in early colonization of the lower respiratory tracts of children with cystic fibrosis [23,24]. |
| PubMedID- 25568518 | Next by the frequency is acute bronchitis with 10%, chronic obstructive pulmonary disease (copd) with 7%, while chronic bronchitis was present in only 4%. |
| PubMedID- 21857781 | Patients with chronic obstructive pulmonary disease (copd) exhibit dominant features of chronic bronchitis, emphysema, and/or asthma, with a common phenotype of airflow obstruction. |
| PubMedID- 22284994 | Background: roflumilast is a newly approved phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and a history of exacerbations. |
| PubMedID- 26528246 | Impaired mucociliary clearance (mcc) is a hallmark of acquired chronic airway diseases like chronic bronchitis associated with chronic obstructive pulmonary disease (copd) and asthma. |
| PubMedID- 24152603 | Objective: roflumilast is the first phosphodiesterase 4 (pde4) inhibitor approved for the treatment of chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and history of exacerbations. |
Page: 1